FDA Refers Reckitt To FTC For Hindering Generic Suboxone
The U.S. Food and Drug Administration on Friday approved the production of two generic versions of Reckitt Benckiser Pharmaceuticals Inc.'s opioid dependence treatment Suboxone, rebuking the company for hindering generic competition...To view the full article, register now.
Already a subscriber? Click here to view full article